High-risk CLL remains a clinical challenge, even in the era of the novel targeted agents, such as ibrutinib, venetoclax and idelalisib. Particularly Richter transformation, which is a common presentation of relapsed disease after targeted therapy, remains very difficult to treat. In the second funding period of the KFO-286, we began to focus our efforts on characterizing high-risk CLL, as well as the discovery of molecular mechanisms of drug resistance and transformation. To further engage with the scientific community working on aggressive lymphomas and transformed disease, we organized the Cologne DLBCL Symposium. The first meeting takes place on February 1st in the new lecture hall of the Max Planck Institute for Aging Research in Cologne. We have assembled an illustrious list of confirmed speakers, as well as numerous poster presentations (Download Programme here). The symposium is organized and co-funded by the KFO-286 (led by M. Hallek and C. Reinhardt) and the Center for Integrated Oncology Cologne-Bonn (CIO, speaker M. Hallek).